MLICM
ADVM

Metropolitan Life Insurance Company (MetLife)’s Adverum Biotechnologies ADVM Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,405
Closed -$237K – 2711
2021
Q1 		$237K Sell
2,405
-177
-7% -$21.3K ﹤0.01% 1898
2020
Q4 		$280K Hold
2,582
– – ﹤0.01% 1717
2020
Q3 		$266K Buy
2,582
+330
+15% +$49.4K ﹤0.01% 1602
2020
Q2 		$470K Buy
2,252
+263
+13% +$46.6K 0.01% 1250
2020
Q1 		$194K Buy
1,989
+515
+35% +$60K ﹤0.01% 1606
2019
Q4 		$170K Sell
1,474
-591
-29% -$52.1K ﹤0.01% 2035
2019
Q3 		$113K Hold
2,065
– – ﹤0.01% 2236
2019
Q2 		$246K Hold
2,065
– – ﹤0.01% 1761
2019
Q1 		$108K Buy
+2,065
New +$83.5K ﹤0.01% 2285
2018
Q4 		– Sell
-2,002
Closed -$121K – 2548
2018
Q3 		$121K Hold
2,002
– – ﹤0.01% 2341
2018
Q2 		$106K Buy
+2,002
New +$120K ﹤0.01% 2288
2015
Q4 		– Sell
-1,478
Closed -$122K – 2580
2015
Q3 		$122K Hold
1,478
– – ﹤0.01% 2547
2015
Q2 		$240K Buy
+1,478
New +$499K ﹤0.01% 2275
2015
Q1 		– Sell
-569
Closed -$307K – 2220
2014
Q4 		$307K Sell
569
-297
-34% -$114K ﹤0.01% 2111
2014
Q3 		$296K Buy
+866
New +$258K ﹤0.01% 2089

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ADVM Position: Q2 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 2,405 shares — an estimated $237K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ADVM in Q3 2014 and held it in 15 quarters. The position peaked at $470K in Q2 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,405 Adverum Biotechnologies shares in Q2 2021, an estimated $237K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 15 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Adverum Biotechnologies position peaked at $470K in Q2 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2021, filed 16 Aug 2021.